LONA

LeonaBio, Inc. develops novel therapeutics aimed at addressing diseases with significant unmet medical needs, specifically treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The company focuses on advancing its drug candidates through clinical development to improve patient outcomes. LeonaBio operates primarily in the biotechnology sector, targeting healthcare providers and patients in the oncology and neurology markets.